Psoriasis Clinical Trials

Showing 221-240 of 478 trials

JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

NCT04792957

The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG). In this study JAK/STAT signaling pathway will be investigated in the skin biopsies of PG patients

Pyoderma GangrenosumHidradenitis SuppurativaPsoriasis

Dokuz Eylul University120 participantsStarted May 2022

COMPLETEDPHASE3

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299

This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.

PsoriasisPsoriatic Arthritis

Amgen250 participantsStarted Oct 2012

Phoenix, Arizona, United States • Bakersfield, California, United States • Irvine, California, United States +79 more locations

JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Related Searches

MYL-1401A Efficacy and Safety Comparability Study to Humira®

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

Ultrasound Enthesitis Response in Psoriatic Arthritis

HIV Indicator Diseases in Hospital and Primary Care

bIosimilar of aDalimumab, an European evAluation

Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis

Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece

Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Lifestyle Modification in Psoriatic Patients With Fatty Liver

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults